Proliferation-dependent and -independent cytotoxicity by antitumor diarylsulfonylureas: Indication of multiple mechanisms of drug action

作者: Janek Sosinski , Jay H. Thakar , Glen S. Germain , Franklin C. Harwood , Peter J. Houghton

DOI: 10.1016/0006-2952(93)90027-T

关键词: In vitroCytotoxicityCell growthApoptosisMechanism of actionDNA damageMolecular biologyBiochemistryCell divisionBiologyISCU

摘要: The mechanism(s) by which antitumor diarylsulfonylureas (DSU) cause cytotoxicity has been examined in GC3/c1 human colon adenocarcinoma cells and a subline selected for resistance to N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)urea (ISCU). Resistance was stable the absence of selection pressure. This mutant (designated LYC5) 5.5-fold resistant ISCU compared parental serum containing medium when were exposed 7 days. In contrast, LYC5 not 4-hr exposure ISCU. These data indicated two possible mechanisms action, dependent on concentration time Proliferation-dependent -independent identified wild-type clones. serum-free growth factors, IC50 0.51 microM 7.0 (13.6-fold resistance), whereas without factors both lines 8- 9-fold relative conditions cellular proliferation. Accumulation similar quiescent proliferating cells, reduced only slightly cells. Analysis DNA agarose gel electrophoresis showed that nucleosomal ladders formed No detected during toxic concentrations drug (IC90), or after removal addition stimulate growth. indicate several diarylsulfonylurea agents may cell death. at very high (IC50 approximately 370 microM) short periods (4 hr), proliferation independent, equally sensitive. mechanism relate uncoupling activity However, pharmacological relevant concentrations, primary led formation 0.5 microM). A additional occurred higher associated with degradation.

参考文章(16)
P. Houghton, J. Sosinski, J. Thakar, J. Houghton, Diarylsulfonylureas : new anticancer agents with novel activities, toxicities and mechanism of action Springer, Paris. pp. 405- 408 ,(1991) , 10.1007/978-2-8178-0782-9_98
Charles Heidelberger, Makoto Umeda, Comparative Studies of Fluorinated Pyrimidines with Various Cell Lines Cancer Research. ,vol. 28, pp. 2529- 2538 ,(1968)
David S. Wilkinson, Henry C. Pitot, Inhibition of Ribosomal Ribonucleic Acid Maturation in Novikoff Hepatoma Cells by 5-Fluorouracil and 5-Fluorouridine Journal of Biological Chemistry. ,vol. 248, pp. 63- 68 ,(1973) , 10.1016/S0021-9258(19)44445-1
C Chapin, P J Houghton, J H Thakar, R A Ashmun, R H Berg, Effect of Antitumor Diarylsulfonylureas on in Vivo and in Vitro Mitochondrial Structure and Functions Cancer Research. ,vol. 51, pp. 6286- 6291 ,(1991)
J J Howbert, W J Ehlhardt, Metabolism and disposition of p-chloroaniline in rat, mouse, and monkey. Drug Metabolism and Disposition. ,vol. 19, pp. 366- 369 ,(1991)
Peter J. Houghton, Frank C. Bailey, Glen S. Germain, Gerald B. Grindey, J.Jeffry Howbert, Janet A. Houghton, Studies on the cellular pharmacology of N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl)-urea. Biochemical Pharmacology. ,vol. 39, pp. 1187- 1192 ,(1990) , 10.1016/0006-2952(90)90261-I
Mary ER O'Brien, Janet Hardy, Sylvia Tan, Jackie Walling, Brian Peters, Sarah Hatty, Eve Wiltshaw, A phase II study of sulofenur, a novel sulfonylurea, in recurrent epithelial ovarian cancer. Cancer Chemotherapy and Pharmacology. ,vol. 30, pp. 245- 248 ,(1992) , 10.1007/BF00686324
Peter J. Houghton, Janet A. Houghton, Leann Myers, Pamela Cheshire, J. Jeffry Howbert, Gerald B. Grindey, Evaluation of N-(5-indanylsulfonyl)-N′-(4-chlorophenyl)-urea against xenografts of pediatric rhabdomyosarcoma Cancer Chemotherapy and Pharmacology. ,vol. 25, pp. 84- 88 ,(1989) , 10.1007/BF00692344
Peter J. Houghton, Janet A. Houghton, Frank C. Bailey, Glen S. Germain, Gerald B. Grindey, Bryant C. Witt, N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)urea, a novel agent equally cytotoxic to nonproliferating human colon adenocarcinoma cells. Cancer Research. ,vol. 50, pp. 318- 322 ,(1990)
Peter J. Houghton, Pamela M. Torrance, Janet A. Houghton, Glen Germain, Development and characterization of a human colon adenocarcinoma xenograft deficient in thymidine salvage. Cancer Research. ,vol. 47, pp. 2117- 2122 ,(1987)